-
-
Overview
-
Reagent provided: 50µg, 1mg/ml. Tested applications: WB, Dot Blot, FCM. Immunogen: Synthetic Peptide designed from the Thalidomide-binding Region of CRBN protein (339–442 aa). Species reactivity: Reacts with Human. Not yet tested in other species. Description: It is believed that the drug thalidomide binds and inactivates cereblon, which leads to a teratogenic effect on fetal development. Mutations in the CRBN gene are associated with autosomal recessive nonsyndromic mental retardation possibly as a result of dysregulation of calcium-activated potassium channels in the brain during development. Investigators demonstrated that both absence and downregulation of expression of CRBN in human myeloma cells resulted in IMiD resistance in human myeloma cells. Cellular localization: Cytoplasm. Nucleus. Membrane. Clone: CRBN-PoAb. Isotype: Polyclonal. Form: Liquid. Storage instructions: Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. Storage buffer: PBS, pH 7.2. Preservative: None. Method of Purification: Affinity chromatography. Image Data: Detection of CRBN by FCM. The histogram is a representations of H929 cell line. Cells were stained with CRBN PoAb (Green) and Isotype control (Blue). Cells were analyzed on a FACSAria II (Becton Dickinson, San Jose, CA) flow cytometer, using BD FACSDiva software. Detection of CRBN by immunoblotting. Sample: Recombinant Thalidomide binding Region of CRBN protein (339–442 aa). Detection: Chemiluminescence. CRBN PoAb Dilution: 1/1000. 2ª Ab: Anti-Rabbit 1/10000. 30 sec exposition time.
Please contact us at for specific academic pricing.
-
- Properties
- Applications
-
Overview